Although experiments in vitro and in mouse models of diabetes suggest a potential role of GM3 in competing with the insulin–insulin receptor interaction and to contribute to T2D, robust evidence using GM3 synthase specific inhibitors is needed. This evidence concerns the gene ST3GAL5 and type 2 diabetes mellitus.